OBiO Tech(SH:688238) Xin Lang Cai Jing·2025-10-14 01:30Core Insights - He Yuan Bio's stock increased by 0.39% on October 13, with a trading volume of 138 million yuan, indicating positive market sentiment towards the company [1] - The company reported a financing buy-in of 14.76 million yuan and a net financing buy-in of 700,900 yuan on the same day, suggesting active investor interest [1] - As of October 13, the total margin balance for He Yuan Bio reached 160 million yuan, accounting for 3.25% of its market capitalization, which is above the 60th percentile of the past year [1] Financing and Margin Data - On October 13, He Yuan Bio had a financing buy-in of 14.76 million yuan, with a current financing balance of 160 million yuan [1] - The financing balance represents 3.25% of the company's market capitalization, indicating a relatively high level of leverage compared to historical data [1] - The margin trading data shows no short selling activity on October 13, with a margin balance of 0 yuan, placing it in the 80th percentile of the past year [1] Company Overview - He Yuan Bio, established on March 5, 2013, and listed on March 22, 2022, is located in Shanghai and specializes in providing CRO and CDMO services for gene therapy [2] - The company's revenue composition includes 54.75% from CDMO services, 33.96% from CRO services, 10.28% from bioreagents and other products, and 1.02% from regenerative medicine services [2] - As of June 30, the number of shareholders increased by 6.83% to 12,600, while the average circulating shares per person decreased by 6.39% to 50,864 shares [2] Financial Performance - For the first half of 2025, He Yuan Bio achieved a revenue of 120 million yuan, reflecting a year-on-year growth of 6.01% [2] - The company reported a net profit attributable to shareholders of -10.5 million yuan, which is an improvement of 7.74% compared to the previous period [2]